Sydney-based Recce Pharmaceuticals (ASX:RCE), a company developing a new class of broad-spectrum synthetic antibiotics, has updated on progress to begin the first human trials of its lead compound RECCE 327.
The company said 'Intravascular phase 1 Human Clinical Trial' is in the final stages of executing a clinical trial agreement for an independent safety assessment of RECCE 327 at an Australian-based trial facility.
It said it remains on track to deliver this milestone in the current quarter.
Recce said it is also working with an Australian teaching hospital to initiate an independent Phase 1/2 topical efficacy study involving patients with a range of bacterial wound, burn and skin infections.